4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Akebia Therapeutics, Inc. (AKBA) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Cambridge, United States with about 194 employees. Its market capitalization is roughly $327 million. In the fiscal year ended 2025-12-31, AKBA reported $236M in revenue and ($5M) in net income.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Interactive charts & full statements → Open the AKBA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $236M | $160M | $195M | $292M | — |
| Gross Profit | $197M | $97M | $120M | $207M | — |
| Operating Income (EBIT) | $24M | ($50M) | ($46M) | ($65M) | — |
| Net Income | ($5M) | ($69M) | ($52M) | ($94M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $54M | $58M | $59M | $62M | $57M | — |
| Gross Profit | $41M | $45M | $49M | $53M | $50M | — |
| Operating Income (EBIT) | ($5M) | ($9M) | $4M | $14M | $14M | — |
| Net Income | ($9M) | ($12M) | $0M | $0M | $6M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $377M | $221M | $242M | $356M | — |
| Total Liabilities | $344M | $270M | $272M | $351M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AKBA viewer.
About TickerBase · Data methodology & sources